<DOC>
	<DOCNO>NCT01867671</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center study compare peanut oral immunotherapy ( OIT ) placebo induction tolerance desensitization peanut-allergic child . Eligible participant peanut allergy randomly assign receive either peanut OIT placebo 134 week follow peanut avoidance 26 week .</brief_summary>
	<brief_title>Peanut Oral Immunotherapy Children</brief_title>
	<detailed_description>An initial oral food challenge ( OFC ) 1 g peanut flour ( 500 mg peanut protein ) conduct . Participants must clinical reaction OFC initiate study dose . After initial OFC , study design include four phase : - Initial dose escalation ( 1 day ) : Peanut placebo dose give incrementally increase every 20 minute dose 12 mg peanut flour ( 6 mg peanut protein ) placebo flour give . - Build-up ( 30 week ) : Initial observe dose administration high tolerate dose , follow daily OIT home return visit every 2 week dose escalation . - Maintenance ( 104 week ) : The participant continue daily OIT return visit every 13 week . At end phase participant undergo blind OFC 10 g peanut flour ( 5 g peanut protein ) . - Avoidance ( 26 week ) : In final phase participant see every 13 week . At completion phase participant final blind OFC 10g peanut flour ( 5 g peanut protein ) .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Clinical history peanut allergy avoidance peanut without ever eat peanut ; Serum immunoglobulin E ( IgE ) peanut ≥5 kUA/L determine UniCAP™ , invitro test system diagnosis monitoring allergy inflammation ; Wheal ≥ 3mm skin prick test peanut extract compare negative control ; A clinical reaction ingestion 1 g peanut flour ( 500 mg peanut protein ) screen OFC ; Written inform consent parent/guardian . History severe anaphylaxis hypotension peanut ; Documented clinical history allergy oat ; Suspected allergy oat wheal ≥7mm skin prick test oat extract compare negative control ; Chronic disease asthma , atopic dermatitis , rhinitis require therapy ; e.g. , heart disease diabetes ; Active eosinophilic gastrointestinal disease past 2 year ; Participation interventional study treatment food allergy 6 month prior visit 1 ; Inhalant allergen immunotherapy yet reach maintenance dosing ; Severe asthma , indicate repeat hospitalization hospital emergency department visit ; Moderate asthma define accord National Asthma Education Prevention Program Expert ; Panel require fluticasone 440 mcg equivalent daily adequate control ; Inability discontinue antihistamine skin test , OFC initial dose escalation ; Use omalizumab nontraditional form allergen immunotherapy ( e.g. , oral sublingual ) 12 month prior visit 1 ; Any systemic therapy judgment investigator could immunomodulatory ( e.g . rituximab ) 12 month prior visit 1 , systemic corticosteroid therapy total three week allow ; Use investigational drug 90 day prior visit 1 ; Plan use investigational drug study period ; The presence medical condition investigator deem incompatible participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Allergy , Peanut</keyword>
	<keyword>Peanut allergy</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Desensitization , Immunologic</keyword>
</DOC>